4DMT to Present Interim Data from 4D-150 Phase 1/2 PRISM Clinical Trial for Wet AMD at ARVO 2023, and Promotes Robert Kim, M.D. to Chief Medical Officer
13 avr. 2023 08h00 HE
|
4D Molecular Therapeutics, Inc.
Interim data to be presented in an oral presentation by Dr. Arshad M. Khanani, M.D., M.A., FASRS at the 2023 ARVO Annual Meeting on Thursday, April 27, 2023 at 11:30 a.m. ETPromoted Robert Kim, M.D....
4D Molecular Therapeutics Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials & Development Plans for Fabry Disease Cardiomyopathy at WORLDSymposium™
22 févr. 2023 16h05 HE
|
4D Molecular Therapeutics, Inc.
All three patients with 12 months of follow-up demonstrated improvement in multiple FDA-recommended cardiac endpoints at relatively low dose of 1E13 vg/kgCardiac biopsy demonstrated selective and...
4DMT to Present Interim Clinical Data from INGLAXA Phase 1/2 Trials of 4D-310 for Fabry Disease Cardiomyopathy at 19th Annual WORLDSymposium™
16 févr. 2023 16h05 HE
|
4D Molecular Therapeutics, Inc.
Company to host live webcast on Wednesday, February 22, at 4:30 p.m. ESTPlatform presentation to be presented at WORLDSymposium™ on Saturday, February 25 EMERYVILLE, Calif., Feb. 16, 2023 (GLOBE...
4D Molecular Therapeutics to Participate in the SVB Securities Global Biopharma Conference
08 févr. 2023 16h05 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, ‘4DMT’), a clinical-stage biotherapeutics company harnessing the power of directed evolution for...
4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150 Genetic Medicine for the Treatment of Diabetic Macular Edema
02 févr. 2023 16h05 HE
|
4D Molecular Therapeutics, Inc.
4D-150 Phase 2 SPECTRA clinical trial for diabetic macular edema enrollment is expected to initiate in Q3 2023Initial Phase 1 PRISM clinical trial with 4D-150 for wet age-related macular degeneration...
4D Molecular Therapeutics to Participate in Upcoming Investor Conferences
20 sept. 2022 16h15 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for...